GSK's Jem­per­li meets over­all sur­vival pri­ma­ry end­point in PhI­II study

GSK an­nounced that its check­point in­hibitor Jem­per­li added to chemother­a­py helped en­dome­tri­al can­cer pa­tients live longer than chemother­a­py in a Phase III study.

In the 787-pa­tient RU­BY tri­al, peo­ple with ad­vanced or re­cur­rent en­dome­tri­al can­cer re­ceived ei­ther Jem­per­li plus chemother­a­py or a place­bo plus chemother­a­py. And with those who re­ceived the Jem­per­li-chemo treat­ment liv­ing longer than those in the com­para­tor arm, the study has now met its pri­ma­ry over­all sur­vival end­point, ac­cord­ing to GSK on Mon­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER